Abstract
Objectives
CYP2C9 gene polymorphic variants can decrease the effects of losartan, reducing active metabolite (E-3174) formation. Study aims to determine the influence of *2 (+430C>T; rs799853) and *3 (+1075A>C; rs1057910) CYP2C9 gene polymorphic variants on the hypotensive and uricosuric effect of losartan on patients with arterial hypertension.
Methods
Eighty one patients with stage 1–2 arterial hypertension newly diagnosed with ABMP were enrolled in the study. Physicians started losartan treatment and then we measured urine concentration of E-3174/losartan to estimate CYP2C9 activity. After 3-month losartan treatment we compared effectiveness of the therapy with ABPM and plasma uric acid level between carriers of CYP2C9 *1/*1 and CYP2C9 gene polymorphic variants (*2 and *3).
Results
Carriage of CYP2C9*2 and CYP2C9*3 alleles reduced the hypotensive effect of losartan (p<0.001, OR=8.13 (95% CI, 2.75–23.97)). Analysis of the ABPM data revealed that blood pressure was significantly higher in patients with polymorphic genotypes. There was no significant difference in uric acid level in plasma and losartan and its metabolite concentration in urine between genotypes.
Conclusions
Carriage of low function polymorphic variants of the CYP2C9 gene (*2 and *3) reduced the hypotensive effect of losartan according to ABPM and don’t affect uric acid level in plasma and E-3174/losartan in urine.
-
Research funding: This study is supported by the state assignment of the Russian Federation “The novel pharmacogenetic biomarkers of major diseases pharmacotherapy” under Project No. 121110800062-6.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The study has been performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow.
References
1. Isvoran, A, Louet, M, Vladoiu, DL, Craciun, D, Loriot, MA, Villoutreix, BO, et al.. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today 2017;22:366–76. https://doi.org/10.1016/j.drudis.2016.09.015.Search in Google Scholar PubMed
2. Daly, AK, Rettie, AE, Fowler, DM, Miners, JO. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Personalized Med 2017;8:1. https://doi.org/10.3390/jpm8010001.Search in Google Scholar PubMed PubMed Central
3. Fujikura, K, Ingelman-Sundberg, M, Lauschke, VM. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenetics Genom 2015;25:584–94. https://doi.org/10.1097/fpc.0000000000000172.Search in Google Scholar PubMed
4. Zhou, Y, Ingelman-Sundberg, M, Lauschke, VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 2017;102:688–700. https://doi.org/10.1002/cpt.690.Search in Google Scholar PubMed PubMed Central
5. Mirzaev, KB, Fedorinov, DS, Ivashchenko, DV, Sychev, DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics 2019;20:847–65. https://doi.org/10.2217/pgs-2019-0013.Search in Google Scholar PubMed
6. Williams, B, Mancia, G, Spiering, W, Agabiti Rosei, E, Azizi, M, Burnier, M, et al.. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–104.10.1097/HJH.0000000000001940Search in Google Scholar PubMed
7. Suchard, MA, Schuemie, MJ, Krumholz, HM, You, SC, Chen, R, Pratt, N, et al.. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:1816–26. https://doi.org/10.1016/s0140-6736(19)32317-7.Search in Google Scholar PubMed PubMed Central
8. Brenner, BM, Cooper, ME, de Zeeuw, D, Keane, WF, Mitch, WE, Parving, HH, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9. https://doi.org/10.1056/nejmoa011161.Search in Google Scholar
9. Dahlöf, B, Devereux, RB, Kjeldsen, SE, Julius, S, Beevers, G, de Faire, U, et al.. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–03. https://doi.org/10.1016/s0140-6736(02)08089-3.Search in Google Scholar
10. Pitt, B, Poole-Wilson, PA, Segal, R, Martinez, FA, Dickstein, K, Camm, AJ, et al.. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–7. https://doi.org/10.1016/s0140-6736(00)02213-3.Search in Google Scholar PubMed
11. Yasar, U, Tybring, G, Hidestrand, M, Oscarson, M, Ingelman-Sundberg, M, Dahl, ML, et al.. Role of Cyp2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001;29:1051–6.Search in Google Scholar
12. Sica, DA, Gehr, TWB, Ghosh, S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797–814. https://doi.org/10.2165/00003088-200544080-00003.Search in Google Scholar PubMed
13. Yasar, U, Forslund-Bergengren, C, Tybring, G, Dorado, P, Llerena, A, Sjöqvist, F, et al.. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89–98. https://doi.org/10.1067/mcp.2002.121216.Search in Google Scholar PubMed
14. Huang, HX, Wu, H, Zhao, Y, Zhou, T, Ai, X, Dong, Y, et al.. Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. Xenobiotica 2021;51:616–23. https://doi.org/10.1080/00498254.2021.1880670.Search in Google Scholar PubMed
15. de Andrés, F, Terán, S, Bovera, M, Fariñas, H, Terán, E, Llerena, A. Multiplex phenotyping for systems medicine: a one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach. OMICS 2016;20:88–96. https://doi.org/10.1089/omi.2015.0131.Search in Google Scholar PubMed
16. Ripley, E, Hirsch, A. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovascular Dis 2010;3:93–8. https://doi.org/10.2147/ijnrd.s7038.Search in Google Scholar PubMed PubMed Central
17. Wolff, ML, Cruz, JL, Vanderman, AJ, Brown, JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis 2015;6:339–46. https://doi.org/10.1177/2040622315596119.Search in Google Scholar PubMed PubMed Central
18. Sutton Burke, EM, Kelly, TC, Shoales, LA, Nagel, AK. Angiotensin receptor blockers effect on serum uric acid-A class effect? J Pharm Pract 2020;33:874–81. https://doi.org/10.1177/0897190019866315.Search in Google Scholar PubMed
19. Iwanaga, T, Sato, M, Maeda, T, Ogihara, T, Tamai, I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Therapeut 2007;320:211–7. https://doi.org/10.1124/jpet.106.112755.Search in Google Scholar PubMed
20. Hamada, T, Ichida, K, Hosoyamada, M, Mizuta, E, Yanagihara, K, Sonoyama, K. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;20:1157–62. https://doi.org/10.1038/ajh.2008.245.Search in Google Scholar PubMed
21. Miao, Y, Ottenbros, SA, Laverman, GD, Brenner, BM, Cooper, ME, Parving, HH, et al.. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension 2011;58:2–7. https://doi.org/10.1161/hypertensionaha.111.171488.Search in Google Scholar
22. Khanna, D, Fitzgerald, JD, Khanna, PP, Bae, S, Singh, MK, Neogi, T, et al.. 2021 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46. https://doi.org/10.1002/acr.21772.Search in Google Scholar PubMed PubMed Central
23. Joy, MS, Dornbrook-Lavender, K, Blaisdell, J, Hilliard, T, Boyette, T, Hu, Y, et al.. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol 2009;65:947–53. https://doi.org/10.1007/s00228-009-0707-7.Search in Google Scholar PubMed PubMed Central
24. Falvella, FS, Marelli, S, Cheli, S, Montanelli, S, Viecca, F, Salvi, L, et al.. Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen? Drug Metab Pers Ther 2016;31:157–63. https://doi.org/10.1515/dmpt-2016-0006.Search in Google Scholar PubMed
25. Parati, G, Stergiou, G, O’Brien, E, Asmar, R, Beilin, L, Bilo, G, et al.. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014;32:1359–66. https://doi.org/10.1097/hjh.0000000000000221.Search in Google Scholar
26. Sun, H, Qu, Q, Qu, J, Lou, XY, Peng, Y, Zeng, Y, et al.. URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics 2015;16:855–63. https://doi.org/10.2217/pgs.15.52.Search in Google Scholar PubMed
27. Wu, L, Fan, Y, Wang, Y, Li, Z, Mao, D, Zhuang, W. The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. J Clin Lab Anal 2021;35:e23949. https://doi.org/10.1002/jcla.23949.Search in Google Scholar PubMed PubMed Central
28. Sweet, CS, Bradstreet, DC, Berman, RS, Jallard, N, Saenz, A, Weidler, DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994;7:1035–40. https://doi.org/10.1093/ajh/7.12.1035.Search in Google Scholar PubMed
29. Nakashima, M, Uematsu, T, Kosuge, K, Kanamaru, M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333–5. https://doi.org/10.1007/bf00266358.Search in Google Scholar PubMed
30. Park, YA, Song, YB, Yee, J, Yoon, HY, Gwak, HS. Influence of cyp2c9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite e-3174: a systematic review and meta-analysis. J Personalized Med 2021;11:617. https://doi.org/10.3390/jpm11070617.Search in Google Scholar PubMed PubMed Central
© 2022 Walter de Gruyter GmbH, Berlin/Boston
